Healthcare Professionals

• Introduction
• Cancer
• Cardiovascular Diseases
• Infectious Diseases
• CNS Infections
• Gastro-Intestinal Infections
• Hepatitis
• HIV / AIDS
• Infectious Mononucleosis
• Mother-to-child Transmission
• Respiratory Infections
• Sepsis
• Sexually Transmitted Infections
• Tuberculosis
• Urinary Tract Infections
• Healthcare Associated Infections

Infectious Diseases

Sepsis

Every year, severe sepsis strikes more than 750,000 people in the United States, 215,000 of whom die. Sepsis with acute organ dysfunction (severe sepsis) is the leading cause of death in the non-coronary intensive care unit (1). Despite the enormous investment in critical care resources, severe sepsis mortality ranges from 28% to 50% or greater. Read more in our Sepsis Fact Sheet –›

Early diagnosis of sepsis is key for improved survival FDA Clears bioMérieux's VIDAS® B.R.A.H.M.S PCT Assay A First Indication for Sepsis Risk Assessment in the ICU Read more Since the microbiological origin of infection is only demonstrated in about 2/3rd of cases, an expanded list of clinical and laboratory variables need to be taken into account for diagnosis, prognosis and monitoring response to therapy. Together, these variables help assess the severity of the inflammatory response and organ dysfunction. Host response biomarkers such as procalcitonin (PCT) and C-reactive protein (CRP) are now being recognized as useful tools in the diagnostic process. 1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10. Read more: What is sepsis? What are the different forms of sepsis? Diagnosing sepsis Sepsis – key points Guidelines and weblinks for the management of patients with sepsis What is the clinical interest of procalcitonin? Procalcitonin – key points

bioMérieux solutions for diagnosing sepsis Blood cultures: BacT/ALERT® 3D modular range of automated blood culture systems for real-time monitoring of blood samples.    Identification and antibiotic susceptibility testing: VITEK 2 and VITEK 2 Compact: range of fully automated identification and susceptibility testing systems Etest®: gradient technique for on-scale determination of MIC values for antibiotics, antifungal and antimycobacterial agents   Procalcitonin (new marker of bacterial infection): VIDAS® B.R.A.H.M.S. Procalcitonin is an automated test for early diagnosis and monitoring of sepsis and bacterial infection and is adapted to emergency situations (visit also: www.procalcitonin.com).